NASDAQ: ATRC

Atricure Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: ATRC) stock is to Strong Buy ATRC stock.

Out of 6 analysts, 3 (50%) are recommending ATRC as a Strong Buy, 3 (50%) are recommending ATRC as a Buy, 0 (0%) are recommending ATRC as a Hold, 0 (0%) are recommending ATRC as a Sell, and 0 (0%) are recommending ATRC as a Strong Sell.

If you're new to stock investing, here's how to buy Atricure stock.

(NASDAQ: ATRC) Atricure's forecast annual revenue growth rate of 15% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Atricure's revenue in 2024 is $399,245,000.On average, 4 Wall Street analysts forecast ATRC's revenue for 2024 to be $21,968,841,740, with the lowest ATRC revenue forecast at $21,899,981,953, and the highest ATRC revenue forecast at $22,033,228,258. On average, 4 Wall Street analysts forecast ATRC's revenue for 2025 to be $25,072,053,003, with the lowest ATRC revenue forecast at $24,831,400,659, and the highest ATRC revenue forecast at $25,293,003,929.

In 2026, ATRC is forecast to generate $28,346,533,355 in revenue, with the lowest revenue forecast at $28,095,935,126 and the highest revenue forecast at $28,744,083,223.

According to 6 Wall Street analysts that have issued a 1 year ATRC price target, the average ATRC price target is $48.00, with the highest ATRC stock price forecast at $60.00 and the lowest ATRC stock price forecast at $32.00.

On average, Wall Street analysts predict that Atricure's share price could reach $48.00 by Apr 23, 2025. The average Atricure stock price prediction forecasts a potential upside of 108.24% from the current ATRC share price of $23.05.

(NASDAQ: ATRC) forecast ROE is N/A, which is considered weak.